Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. - Wikidata - wikimedia - TriplyDB

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

http://www.wikidata.org/entity/Q37090982

about

Heart failure with preserved ejection fraction: emerging drug strategies Cardiac biomarkers: new tools for heart failure management Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling.Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension.Cardiac aging and heart disease in humans Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality.The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy Metabolomic fingerprint of heart failure with preserved ejection fraction.The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged >=65 years with heart failure.Regional Strain Analysis with Multidetector CT in a Swine Cardiomyopathy Model: Relationship to Cardiac MR Tagging and Myocardial Fibrosis.MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study.Biochemical markers of aging for longitudinal studies in humans.Aldosterone and cardiovascular disease: the heart of the matter.Integrating the myocardial matrix into heart failure recognition and management.B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study.Novel biomarkers in human terminal heart failure and under mechanical circulatory support.Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.Molecular and cellular basis for diastolic dysfunction.New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Relationship between B-type natriuretic peptide serum level, echocardiographic TEI index and the degree of diastolic dysfunction in patients with heart failure with preserved systolic function.Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction.Caveolin-1 modulates TGF-β1 signaling in cardiac remodeling.Prognosis of new-onset heart failure outpatients and collagen biomarkers.Pressure overload induces early morphological changes in the heart.Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study.Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.Human heart failure with preserved ejection versus feline cardiomyopathy: what can we learn from both veterinary and human medicine?Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?The future diagnosis of heart failure with normal ejection fraction: less imaging, more biomarkers?Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis.

P2860

Q24595118-5FFADB05-4A49-4594-8BBE-4DB8709B7C94 Q26991726-B9CE7F39-48D4-491F-9D13-95BB130CFF2B Q30659130-DC1A9C34-A400-4798-AC98-85F0B7A0F33B Q33559608-EA7A276A-7D56-41A1-86DE-2970F5CF7637 Q33639771-2DDE433E-A645-43C2-9FC2-64E8EF0033CE Q33810217-D9B10BF7-D041-4DA3-9484-847DEF654E3A Q34222299-D46CFA45-4E3E-4E7E-A458-8AA9FF4C44D5 Q34343385-99EC7CBD-6ED2-4B2C-BB1C-71CE302CEEC2 Q34528187-6778FEBD-9F19-4B90-80BA-387E486945C3 Q35125156-839B9745-9459-4BB2-B228-6382108B03AA Q35641415-D67C214A-956E-450E-B26E-F62375635AD0 Q35686798-57172421-43F0-4706-8FE9-F40FDA52333F Q35777180-CD11F510-FAEB-4762-9051-1356814281FE Q36185869-58660AA1-5F8B-41C1-A26F-0B044ACCFD9A Q36253578-02BC9580-823E-4B2D-9C39-817BCDB9BC77 Q36449881-28354956-DA38-4304-B509-D74484CD496A Q36494721-C9D623D0-A882-4436-B103-352959FC5CA7 Q37406111-F32C46FE-4833-4847-8582-D961673F004B Q37833104-350A20B6-7441-4E56-98D1-D8F89ADD03BA Q37894731-4E3561E5-7958-4946-85CC-2632344CC988 Q37895982-5BA8737A-FE01-43FA-9D0B-13D0E1C89E7F Q38038531-61A7CB58-9FE6-4F63-A41E-66AA0E550024 Q38100987-87B66820-D335-475D-A6D8-9A9724EF1378 Q38110226-1F870DD9-E70F-4961-9854-04EC63F23383 Q38121745-71FC5836-896A-4F26-A1CA-32A8B6841D88 Q38134311-BDCB9296-92A3-4D73-A85C-AB18F232E0CE Q38152289-F6EA0EC4-8BD0-4438-8AFF-E7144F3FEB3F Q38427211-537791EC-ABCB-4386-9093-78448881446A Q40415386-21A79C67-FDAF-4645-9BA8-549F8C52A489 Q40963394-3D139F5D-5176-41C3-93BB-EC12B160299A Q41480610-088EA666-0AB8-4FE2-9904-82B54E20E1B1 Q41666901-4DDE3417-E4F0-4B96-90F6-25A7FAD01F77 Q41840219-3D286176-8AB1-44CE-9555-70961E93B48B Q44565921-D3EB5986-8213-41DB-98C4-20D1B82DF78A Q47392248-3E556096-95F0-4C2D-9E6F-538CB2DE7F87 Q48156451-F648EA2A-5863-4A6E-92C1-89777A12C1B6 Q48247164-AE388BAC-489C-495D-AA05-A7F82A589796 Q49106557-B86709E4-8D69-474D-B7F4-C44B7EC09D41 Q51687690-C790E0D2-9394-477A-82DB-66245C2FA8EF Q53580573-AF5B3222-9AAD-4D15-91CA-8FAEA6445D7D

P2860

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

http://www.wikidata.org/entity/Q37090982

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Diagnosis of heart failure wit ...... markers of collagen turnover.

@en

Diagnosis of heart failure wit ...... markers of collagen turnover.

@nl

type

label

Diagnosis of heart failure wit ...... markers of collagen turnover.

@en

Diagnosis of heart failure wit ...... markers of collagen turnover.

@nl

prefLabel

Diagnosis of heart failure wit ...... markers of collagen turnover.

@en

Diagnosis of heart failure wit ...... markers of collagen turnover.

@nl

P1433

Q37090982-41821B6A-E4F8-41DA-B466-DFE7BFB4E49F

P1476

Q37090982-E8BE8A16-4E60-4937-9A66-1761402C2ADC

P2093

Q37090982-017757D4-2AEF-40B5-A8BB-00C8247A857A

Q37090982-25447553-7F16-475F-8CA0-442F889975C9

Q37090982-4D367C40-461E-44CF-8629-F30299E2147D

Q37090982-6A839896-FF61-4342-A231-E9B663C97B6F

Q37090982-8E77AC24-80DB-428D-9F26-7A0D5F2E48AB

Q37090982-9A669C83-53EF-4684-9F7B-1BBC733D8F01

Q37090982-A6246B68-1376-44C4-9BBD-CF1FA51D8AD9

P2860

Q37090982-0B5336B7-D36A-46CB-BDA9-6BA5E1AC8369

Q37090982-0C2E6E74-7B49-49F8-91DF-3E910EDECF2A

Q37090982-0CEA6E06-7B00-459E-95F2-F6C4F3F07825

Q37090982-167921B4-275D-49EA-B12D-7B4A21030EEA

Q37090982-1D013B8D-08C4-40F9-9649-E55B232FE117

Q37090982-3305D190-572E-417F-B676-F8D08041DB69

Q37090982-39C00ED2-8E96-4E43-A9CA-76E87ECD64DD

Q37090982-3ACDF6A9-ECE9-450D-979E-04102B54497E

Q37090982-3F9A38BF-4249-484A-B59B-3BA747E07D68

Q37090982-5C7B847D-B7B6-4E7A-A12F-EFC77698D9A4

P304

Q37090982-71667E3B-01D4-411F-B920-01950BA185F1

P31

Q37090982-017BB974-9F05-4A7A-9EBC-76462A2CF0F0

P356

Q37090982-6536A83B-B47F-4A3D-8640-E72D8369EF2F

P433

Q37090982-AB66A95B-85B4-40FF-B484-CCFA9322CD2D

P478

Q37090982-2CC0B5A8-6CFF-4241-93B3-94F4DA0001A9

P50

Q37090982-88EDF88F-E1D1-4D48-96B7-7E179647B6E1

Q37090982-97B3C1A0-0318-4A61-94F7-F74A84533AFB

P577

Q37090982-D360FE27-A013-4499-A62E-0E37A06014CF

P5875

Q37090982-2BA3D84B-C3A1-42C6-B638-35F01E62DEE1

P698

Q37090982-3A756F22-D93D-4280-AEDA-C4C59D274720

P921

Q37090982-8F9A22C9-FE3A-48E6-84D0-3FC7AF85FBDA

Q37090982-e1364f76-62f9-4cc8-b443-bf549aa33250

P932

Q37090982-F8F04421-B939-49B8-8468-A8C737C66CEA

P356

P1433

European Journal of Heart Failure

P1476

Diagnosis of heart failure wit ...... f markers of collagen turnover

@en

P2093

Anil Patle

http://www.w3.org/2001/XMLSchema#string

Carmel Conlon

http://www.w3.org/2001/XMLSchema#string

Christina O'Loughlin

http://www.w3.org/2001/XMLSchema#string

John Baugh

http://www.w3.org/2001/XMLSchema#string

Kenneth McDonald

http://www.w3.org/2001/XMLSchema#string

Niamh F Murphy

http://www.w3.org/2001/XMLSchema#string

Ramón Martos

http://www.w3.org/2001/XMLSchema#string

P2860

New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.

The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T.

Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction?

Heart failure with preserved left ventricular systolic function: a hospital cohort study

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Echocardiographic features and brain natriuretic peptides in patients presenting with heart failure and preserved systolic function.

Clinical practice. Diastolic heart failure.

The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.

Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions.

Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements

P304

191-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFN036

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Seamas C. Donnelly

Mark T Ledwidge

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23938830

http://www.w3.org/2001/XMLSchema#string

P698

19168518

http://www.w3.org/2001/XMLSchema#string

P921

P932

2639413

http://www.w3.org/2001/XMLSchema#string